European patent for AppDx® smartphone reader
Abingdon Health plc has announced the granting of a new European patent, EP4150565, for its AppDx® lateral flow smartphone reader, following recent patent grants in the USA and UK. This AppDx® technology is a software development kit that utilizes smartphone cameras and deep learning algorithms to read colorimetric lateral-flow tests, enabling qualitative and semi-quantitative results. The company views this as a valuable tool for its contract development and manufacturing customers, highlighting ongoing innovation in the lateral flow market.
Select text to share a quote on X · sign in to keep highlights & notes in your ABDX notes
York, U.K. 18 December 2025: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces the granting of an additional patent for its AppDx® lateral flow smartphone reader.
The new European patent "Assay Reading Method" with patent number EP4150565 has been granted and follows the recent granting of a similar patent in USA with patent number US 12,373,946 B2, with other patents already granted in UK.
AppDx® is a software development kit for reading colorimetric lateral-flow tests organized for Android™ and iOS® smartphone operating systems. AppDx® enables lateral-flow test readout from your pocket, enabled by a smartphone camera. It consists of a software application programming interface accessed as a library which contains algorithms for image processing and deep learning in order to read a lateral-flow test using a smartphone. The algorithms are customized and tuned for each test. The Abingdon Health AppDx® algorithm reads the lateral flow device qualitatively (e.g. positive/negative) and semi-quantitively (e.g. negative/high/medium/low).
Dr Chris Hand, Executive Chairman of Abingdon Health plc, commented:
"We are pleased to announce the granting of a further patent for our AppDx® lateral flow smartphone lateral flow reader. This is another tool available to our contract development and manufacturing customers and illustrates the continued innovation in the lateral flow market."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.